CLAIMS:

1. An immunoconjugate comprising an antibody covalently attached to one or more 8-Cyc-2-aminobenzazepine moieties by a linker, and having Formula I:

$$Ab–[L–CycBz]_p \qquad I$$


or a pharmaceutically acceptable salt thereof,

wherein:

Ab is an antibody construct that has an antigen binding domain that binds PD-L1;

p is an integer from 1 to 8;

CycBz is the 8-Cyc-2-aminobenzazepine moiety having the formula:



Cyc is selected from the group consisting of phenyldiyl, heterocyclyldiyl and heteroaryldiyl;

R^1, R^2, R^3, and R^4 are independently selected from the group consisting of H, C_1-C_{12} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{12} carbocyclyl, C_6-C_{20} aryl, C_2-C_9 heterocyclyl, and C_1-C_{20} heteroaryl, where alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl, and heteroaryl are independently and optionally substituted with one or more groups selected from:

–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–(C_1-C_{12} alkyldiyl)–OR^5;

–(C_3-C_{12} carbocyclyl);

–(C_3-C_{12} carbocyclyl)–*;

–(C_3-C_{12} carbocyclyl)–(C_1-C_{12} alkyldiyl)–NR^5–*;

–(C_3-C_{12} carbocyclyl)–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–(C_3-C_{12} carbocyclyl)–NR^5–C(=NR^5)NR^5–*;

–(C_6-C_{20} aryl);

–(C_6-C_{20} aryldiyl)–*;

–(C_6-C_{20} aryldiyl)–N(R^5)–*;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–(C_2-C_{20} heterocyclyldiyl)–*;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–NR^5–C(=NR^{5a})N(R^5)–*;

–(C_2-C_{20} heterocyclyl);

–(C_2-C_{20} heterocyclyl)–*;

–(C_2-C_9 heterocyclyl)–(C_1-C_{12} alkyldiyl)–NR^5–*;

–(C_2-C_9 heterocyclyl)–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–(C_2-C_9 heterocyclyl)–C(=O)–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–(C_2-C_9 heterocyclyl)–NR^5–C(=NR^{5a})NR^5–*;

–(C_2-C_9 heterocyclyl)–NR^5–(C_6-C_{20} aryldiyl)–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–(C_2-C_9 heterocyclyl)–(C_6-C_{20} aryldiyl)–*;

–(C_1-C_{20} heteroaryl);

–(C_1-C_{20} heteroaryl)–*;

–(C_1-C_{20} heteroaryl)–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–(C_1-C_{20} heteroaryl)–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–(C_1-C_{20} heteroaryl)–NR^5–C(=NR^{5a})N(R^5)–*;

–(C_1-C_{20} heteroaryl)–N(R^5)C(=O)–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–C(=O)–*;

–C(=O)–(C_1-C_{12} alkyldiyl)–N(R^5)–*;

–C(=O)–(C_2-C_{20} heterocyclyldiyl)–*;

–C(=O)N(R^5)$_2$;

–C(=O)N(R^5)–*;

–C(=O)N(R^5)–(C_1-C_{12} alkyldiyl)–N(R^5)C(=O)R^5;

–C(=O)N(R^5)–(C_1-C_{12} alkyldiyl)–N(R^5)C(=O)N(R^5)$_2$;

–C(=O)NR^5–(C_1-C_{12} alkyldiyl)–N(R^5)CO_2R^5;

–C(=O)NR^5–(C_1-C_{12} alkyldiyl)–N(R^5)C(=NR^{5a})N(R^5)$_2$;

–C(=O)NR^5–(C_1-C_{12} alkyldiyl)–NR^5C(=NR^{5a})R^5;

–C(=O)NR^5–(C_1-C_8 alkyldiyl)–NR^5(C_2-C_5 heteroaryl);

–C(=O)NR^5–(C_1-C_{20} heteroaryldiyl)–N(R^5)–*;

–C(=O)NR^5–(C_1-C_{20} heteroaryldiyl)–*;

–C(=O)NR^5–(C_1-C_{20} heteroaryldiyl)–(C_1-C_{12} alkyldiyl)–N(R^5)$_2$;

–C(=O)NR^5–(C$_1$-C$_{20}$ heteroaryldiyl)–(C$_2$-C$_{20}$ heterocyclyldiyl)–C(=O)NR^5–(C$_1$-C$_{12}$ alkyldiyl)–NR^5–*;

–N(R^5)$_2$;

–N(R^5)–*;

–N(R^5)C(=O)R^5;

–N(R^5)C(=O)–*;

–N(R^5)C(=O)N(R^5)$_2$;

–N(R^5)C(=O)N(R^5)–*;

–N(R^5)CO$_2$R^5;

–NR^{5}C(=NR^{5a})N(R^5)$_2$;

–NR^{5}C(=NR^{5a})N(R^5)–*;

–NR^{5}C(=NR^{5a})R^5;

–N(R^5)C(=O)–(C$_1$-C$_{12}$ alkyldiyl)–N(R^5)–*;

–N(R^5)–(C$_2$-C$_5$ heteroaryl);

–N(R^5)–S(=O)$_2$–(C$_1$-C$_{12}$ alkyl);

–O–(C$_1$-C$_{12}$ alkyl);

–O–(C$_1$-C$_{12}$ alkyldiyl)–N(R^5)$_2$;

–O–(C$_1$-C$_{12}$ alkyldiyl)–N(R^5)–*;

–O–C(=O)N(R^5)$_2$;

–O–C(=O)N(R^5)–*;

–S(=O)$_2$–(C$_2$-C$_{20}$ heterocyclyldiyl)–*;

–S(=O)$_2$–(C$_2$-C$_{20}$ heterocyclyldiyl)–(C$_1$-C$_{12}$ alkyldiyl)–N(R^5)$_2$;

–S(=O)$_2$–(C$_2$-C$_{20}$ heterocyclyldiyl)–(C$_1$-C$_{12}$ alkyldiyl)–NR^5–*; and

–S(=O)$_2$–(C$_2$-C$_{20}$ heterocyclyldiyl)–(C$_1$-C$_{12}$ alkyldiyl)–OH;

or R^2 and R^3 together form a 5- or 6-membered heterocyclyl ring;

X^1, X^2, X^3, and X^4 are independently selected from the group consisting of a bond, C(=O), C(=O)N(R^5), O, N(R^5), S, S(O)$_2$, and S(O)$_2$N(R^5);

R^5 is independently selected from the group consisting of H, C$_6$-C$_{20}$ aryl, C$_3$-C$_{12}$ carbocyclyl, C$_6$-C$_{20}$ aryldiyl, C$_1$-C$_{12}$ alkyl, and C$_1$-C$_{12}$ alkyldiyl, or two R^5 groups together form a 5- or 6-membered heterocyclyl ring;

R^{5a} is selected from the group consisting of C$_6$-C$_{20}$ aryl and C$_1$-C$_{20}$ heteroaryl;

where the asterisk * indicates the attachment site of L, and where one of R^1, R^2, R^3 and R^4 is attached to L;

L is the linker selected from the group consisting of:

–C(=O)–PEG–;

–C(=O)–PEG–C(=O)N(R^6)–(C_1-C_{12} alkyldiyl)–C(=O)–Gluc–;

–C(=O)–PEG–O–;

–C(=O)–PEG–O–C(=O)–;

–C(=O)–PEG–C(=O)–;

–C(=O)–PEG–C(=O)–PEP–;

–C(=O)–PEG–N(R^6)–;

–C(=O)–PEG–N(R^6)–C(=O)–;

–C(=O)–PEG–N(R^6)–PEG–C(=O)–PEP–;

–C(=O)–PEG–N^+(R^6)$_2$–PEG–C(=O)–PEP–;

–C(=O)–PEG–C(=O)–PEP–N(R^6)–(C_1-C_{12} alkyldiyl)–;

–C(=O)–PEG–C(=O)–PEP–N(R^6)–(C_1-C_{12} alkyldiyl)N(R^6)C(=O)–(C_2-C_5 monoheterocyclyldiyl)–;

–C(=O)–PEG–SS–(C_1-C_{12} alkyldiyl)–OC(=O)–;

–C(=O)–PEG–SS–(C_1-C_{12} alkyldiyl)–C(=O)–;

–C(=O)–(C_1-C_{12} alkyldiyl)–C(=O)–PEP–;

–C(=O)–(C_1-C_{12} alkyldiyl)–C(=O)–PEP–N(R^6)–(C_1-C_{12} alkyldiyl)–;

–C(=O)–(C_1-C_{12} alkyldiyl)–C(=O)–PEP–N(R^6)–(C_1-C_{12} alkyldiyl)–N(R^5)–C(=O);

–C(=O)–(C_1-C_{12} alkyldiyl)–C(=O)–PEP–N(R^6)–(C_1-C_{12} alkyldiyl)–N(R^6)C(=O)–(C_2-C_5 monoheterocyclyldiyl)–;

–succinimidyl–(CH_2)$_m$–C(=O)N(R^6)–PEG–;

–succinimidyl–(CH_2)$_m$–C(=O)N(R^6)–PEG–C(=O)N(R^6)–(C_1-C_{12} alkyldiyl)–C(=O)–Gluc–;

–succinimidyl–(CH_2)$_m$–C(=O)N(R^6)–PEG–O–;

–succinimidyl–(CH_2)$_m$–C(=O)N(R^6)–PEG–O–C(=O)–;

–succinimidyl–(CH_2)$_m$–C(=O)N(R^6)–PEG–C(=O)–;

–succinimidyl–(CH_2)$_m$–C(=O)N(R^6)–PEG–N(R^5)–;

–succinimidyl–(CH_2)$_m$–C(=O)N(R^6)–PEG–N(R^5)–C(=O)–;

–succinimidyl–(CH_2)$_m$–C(=O)N(R^6)–PEG–C(=O)–PEP–;

–succinimidyl–(CH_2)$_m$–C(=O)N(R^6)–PEG–SS–(C_1-C_{12} alkyldiyl)–OC(=O)–;

–succinimidyl–(CH_2)$_m$–C(=O)–PEP–N(R^6)–(C_1-C_{12} alkyldiyl)–;


–succinimidyl–$(CH_2)_m$–C(=O)–PEP–N(R^6)–(C_1-C_{12} alkyldiyl)N(R^6)C(=O)–; and

–succinimidyl–$(CH_2)_m$–C(=O)–PEP–N(R^6)–(C_1-C_{12} alkyldiyl)N(R^6)C(=O)–(C_2-C_5 monoheterocyclyldiyl)–;

R^6 is independently H or C_1-C_6 alkyl;


PEG has the formula: $–(CH_2CH_2O)_n–(CH_2)_m–$; m is an integer from 1 to 5, and n is an integer from 2 to 50;

Gluc has the formula:




;

PEP has the formula:



where AA is independently selected from a natural or unnatural amino acid side chain, or one or more of AA, and an adjacent nitrogen atom form a 5-membered ring proline amino acid, and the wavy line indicates a point of attachment;

Cyc is selected from C_6-C_{20} aryldiyl and C_1-C_{20} heteroaryldiyl, optionally substituted with one or more groups selected from F, Cl, NO_2, –OH, $–OCH_3$, and a glucuronic acid having the structure:



;

R^7 is selected from the group consisting of $–CH(R^8)O–$, $–CH_2–$, $–CH_2N(R^8)–$, and $–CH(R^8)O–C(=O)–$, where R^8 is selected from H, C_1-C_6 alkyl, $C(=O)–C_1$-C_6 alkyl, and $–C(=O)N(R^9)_2$, where R^9 is independently selected from the group consisting of H, C_1-C_{12} alkyl, and $–(CH_2CH_2O)_n–(CH_2)_m–OH$, where m is an integer from 1 to 5, and n is an integer from 2 to 50, or two R^9 groups together form a 5- or 6-membered heterocyclyl ring;

y is an integer from 2 to 12;

z is 0 or 1; and

alkyl, alkyldiyl, alkenyl, alkenyldiyl, alkynyl, alkynyldiyl, aryl, aryldiyl, carbocyclyl, carbocyclyldiyl, heterocyclyl, heterocyclyldiyl, heteroaryl, and heteroaryldiyl are independently and optionally substituted with one or more groups independently selected from F, Cl, Br, I, –CN, $–CH_3$, $–CH_2CH_3$, $–CH=CH_2$, $–C≡CH$, $–C≡CCH_3$, $–CH_2CH_2CH_3$, $–CH(CH_3)_2$, $–CH_2CH(CH_3)_2$, $–CH_2OH$, $–CH_2OCH_3$, $–CH_2CH_2OH$, $–C(CH_3)_2OH$, $–CH(OH)CH(CH_3)_2$, $–C(CH_3)_2CH_2OH$, $–CH_2CH_2SO_2CH_3$, $–CH_2OP(O)(OH)_2$, $–CH_2F$, $–CHF_2$, $–CF_3$, $–CH_2CF_3$, $–CH_2CHF_2$, $–CH(CH_3)CN$, $–C(CH_3)_2CN$, $–CH_2CN$, $–CH_2NH_2$, $–CH_2NHSO_2CH_3$, $–CH_2NHCH_3$, $–CH_2N(CH_3)_2$, $–CO_2H$, $–COCH_3$, $–CO_2CH_3$, $–CO_2C(CH_3)_3$, $–COCH(OH)CH_3$, $–CONH_2$, $–CONHCH_3$, $–CON(CH_3)_2$, $–C(CH_3)_2CONH_2$, $–NH_2$, $–NHCH_3$, $–N(CH_3)_2$, $–NHCOCH_3$, $–N(CH_3)COCH_3$, $–NHS(O)_2CH_3$, $–N(CH_3)C(CH_3)_2CONH_2$, $–N(CH_3)CH_2CH_2S(O)_2CH_3$, –NHC(=NH)H, $–NHC(=NH)CH_3$, $–NHC(=NH)NH_2$, $–NHC(=O)NH_2$, $–NO_2$, =O, –OH, $–OCH_3$, $–OCH_2CH_3$, $–OCH_2CH_2OCH_3$, $–OCH_2CH_2OH$, $–OCH_2CH_2N(CH_3)_2$, $–O(CH_2CH_2O)_n–(CH_2)_mCO_2H$, $–O(CH_2CH_2O)_nH$, $–OCH_2F$, $–OCHF_2$, $–OCF_3$, $–OP(O)(OH)_2$, $–S(O)_2N(CH_3)_2$, $–SCH_3$, $–S(O)_2CH_3$, and $–S(O)_3H$.

2. The immunoconjugate of claim 1 wherein the antibody is selected from the group consisting of atezolizumab, durvalumab, and avelumab~~, or a biosimilar or a biobetter thereof~~.

3. The immunoconjugate of claim 1 wherein the antibody construct is a Type A PD-L1 antibody and comprises an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide, wherein:

the immunoglobulin heavy chain variable region polypeptide comprises a complementarity determining region 1 (HCDR1) comprising any one of Type A SEQ ID NOs: 1-23, a complementarity determining region 2 (HCDR2) comprising any one of SEQ ID NOs: 24-57, and a complementarity determining region 3 (HCDR3) comprising any one of SEQ ID NOs: 58-95; or

the immunoglobulin light chain variable region polypeptide comprises a complementarity determining region 1 (LCDR1) comprising any one of SEQ ID NOs: 96-128, a complementarity determining region 2 (LCDR2) comprising any one of SEQ ID NOs: 129-151, and a complementarity determining region 3 (LCDR3) comprising any one of SEQ ID NOs: 152-155~~;~~

~~wherein the sequences are from Figures 1-4~~.

4. The immunoconjugate of claim 1 wherein the antibody construct is a Type A PD-L1 antibody and comprises an immunoglobulin heavy chain variable region of any one of SEQ

ID NOs: 223-264 or at least the CDRs thereof; and an immunoglobulin light chain variable region of any one of SEQ ID NOs: 265-306 or at least the CDRs thereof;

~~wherein the sequences are from Figures 1-4.~~

~~5. The immunoconjugate of claim 1 wherein the antibody construct is a Type A PD-L1 antibody and~~or comprises an immunoglobulin heavy chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 223-264, and an immunoglobulin light chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 265-306~~;~~

~~wherein the sequences are from Figures 1-4~~.

5~~6~~. The immunoconjugate of claim 1 wherein the antibody construct is a Type A PD-L1 antibody and comprises the heavy and light chain immunoglobulin polypeptides, or at least the CDRs thereof~~, of a PD-L1 binding agent of Figures 1A-D~~.

6~~7~~. The immunoconjugate of claim 1 wherein the antibody construct is a Type B PD-L1 antibody and comprises an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide, wherein:

the immunoglobulin heavy chain variable region polypeptide comprises a complementarity determining region 1 (HCDR1) comprising any one of SEQ ID NOs: 1-14, a complementarity determining region 2 (HCDR2) comprising any one of SEQ ID NOs: 15-31, and a complementarity determining region 3 (HCDR3) comprising any one of SEQ ID NOs: 32-52; or

the immunoglobulin light chain variable region polypeptide comprises a complementarity determining region 1 (LCDR1) comprising any one of SEQ ID NOs: 53-67, a complementarity determining region 2 (LCDR2) comprising any one of SEQ ID NOs: 68-79, and a complementarity determining region 3 (LCDR3) comprising any one of SEQ ID NOs: 80-91~~;~~

~~wherein the sequences are from Figures 5-8~~.

7~~8~~. The immunoconjugate of claim 1 wherein the antibody construct is a Type B PD-L1 antibody and comprises an immunoglobulin heavy chain variable region of any one of SEQ ID NOs: 123-143 or at least the CDRs thereof; and an immunoglobulin light chain variable region of any one of SEQ ID NOs: 144-164 or at least the CDRs thereof;

~~wherein the sequences are from Figures 5-8.~~

~~9. The immunoconjugate of claim 1 wherein the antibody construct is a Type B PD-L1 antibody and~~or comprises an immunoglobulin heavy chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 123-143, and

an immunoglobulin light chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 144-164~~;~~

~~wherein the sequences are from Figures 5-8~~.

~~10. The immunoconjugate of claim 1 wherein the antibody construct is a Type B PD-L1 antibody and comprises the heavy and light chain immunoglobulin polypeptides, or at least the CDRs thereof, of a PD-L1 binding agent of Figures 5A-B.~~

~~11~~8. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein X^1 is a bond, and R^1 is H.

~~9~~12. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein X^2 is a bond, and R^2 is C_1-C_8 alkyl.

~~13~~10. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein X^2 and X^3 are each a bond, and R^2 and R^3 are independently selected from C_1-C_8 alkyl, –O–(C_1-C_{12} alkyl), –(C_1-C_{12} alkyldiyl)–OR^5, –(C_1-C_8 alkyldiyl)–$N(R^5)CO_2R^5$, –(C_1-C_{12} alkyl)–$OC(O)N(R^5)_2$, –O–(C_1-C_{12} alkyl)–$N(R^5)CO_2R^5$, and –O–(C_1-C_{12} alkyl)–$OC(O)N(R^5)_2$.

~~14~~11. The immunoconjugate of claim ~~13~~10 wherein R^2 is C_1-C_8 alkyl and R^3 is –(C_1-C_8 alkyldiyl)–$N(R^5)CO_2R^5$.


~~15~~12. The immunoconjugate of claim ~~14~~11 wherein R^2 is $–CH_2CH_2CH_3$ and R^3 is selected from $–CH_2CH_2CH_2NHCO_2$(t-Bu), $–OCH_2CH_2NHCO_2$(cyclobutyl), and $–CH_2CH_2CH_2NHCO_2$(cyclobutyl).

~~16~~13. The immunoconjugate of claim ~~13~~10 wherein R^2 and R^3 are each independently selected from $–CH_2CH_2CH_3$, $–OCH_2CH_3$, $–OCH_2CF_3$, $–CH_2CH_2CF_3$, $–OCH_2CH_2OH$, and $–CH_2CH_2CH_2OH$.

~~17~~14. The immunoconjugate of claim ~~16~~13 wherein R^2 and R^3 are each $–CH_2CH_2CH_3$.

~~18~~15. The immunoconjugate of claim ~~16~~13 wherein R^2 is $–CH_2CH_2CH_3$ and R^3 is $–OCH_2CH_3$.

~~19~~16. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein X^3-R^3 is selected from the group consisting of:




~~20~~17. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein X^4 is a bond, and R^4 is H.

~~21~~18. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein R^1 is attached to L.

~~22~~19. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein R^2 or R^3 is attached to L.

~~23~~20. The immunoconjugate of claim ~~22~~19 wherein X^3–R^3–L is selected from the group consisting of:



where the wavy line indicates the point of attachment to N.

~~24. The immunoconjugate of any one of claims 1 to 10 wherein R^4 is C_1-C_{12} alkyl.~~

~~25. The immunoconjugate of any one of claims 1 to 10 wherein R^4 is –(C_1-C_{12} alkyldiyl)–N(R^5)–*; where the asterisk * indicates the attachment site of L.~~


~~26~~21. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein L is –C(=O)–PEG– or –C(=O)–PEG–C(=O)–.

~~27~~22. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein L is attached to a cysteine thiol of the antibody.

~~28~~23. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein for the PEG, m is 1 or 2, and n is an integer from 2 to 10.

2429. The immunoconjugate of claim 2823 wherein n is 10.

30. The immunoconjugate of any one of claims 1 to 10 wherein L comprises PEP and PEP is a dipeptide and has the formula:




31. The immunoconjugate of claim 30 wherein AA_1 and AA_2 are independently selected from H, $-CH_3$, $-CH(CH_3)_2$, $-CH_2(C_6H_5)$, $-CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, $CHCH(CH_3)CH_3$, CH_2SO_3H, and $CH_2CH_2CH_2NHC(O)NH_2$; or AA_1 and AA_2 form a 5-membered ring proline amino acid.

32. The immunoconjugate of claim 30 wherein AA_1 is $CH(CH_3)_2$, and AA_2 is $CH_2CH_2CH_2NHC(O)NH_2$.


33. The immunoconjugate of claim 30 wherein AA_1 and AA_2 are independently selected from GlcNAc aspartic acid, CH_2SO_3H, and CH_2OPO_3H.

34. The immunoconjugate of claim 30 wherein PEP has the formula:




wherein AA_1 and AA_2 are independently selected from a side chain of a naturally-occurring amino acid.

35. The immunoconjugate of any one of claims 1 to 10 wherein L comprises PEP and PEP is a tripeptide and has the formula:



36. The immunoconjugate of any one of claims 1 to 10 wherein L comprises PEP and PEP is a tetrapeptide and has the formula:



37. The immunoconjugate of claim 36 wherein

AA_1 is selected from the group consisting of Abu, Ala, and Val;


AA_2 is selected from the group consisting of Nle(O-Bzl), Oic and Pro;

AA_3 is selected from the group consisting of Ala and $Met(O)_2$; and


AA_4 is selected from the group consisting of Oic, $Arg(NO_2)$, Bpa, and Nle(O-Bzl).

38. The immunoconjugate of any one of claims 1 to 10 wherein L comprises PEP and PEP is selected from the group consisting of Ala-Pro-Val, Asn-Pro-Val, Ala-Ala-Val, Ala-Ala-Pro-Ala (SEQ ID NO: 473), Ala-Ala-Pro-Val (SEQ ID NO: 474), and Ala-Ala-Pro-Nva (SEQ ID NO: 475).


39. The immunoconjugate of any one of claims 1 to 10 wherein L comprises PEP and PEP is selected from the structures:




;




;





; and




~~40~~25. The immunoconjugate of any one of claims 1 to ~~10~~7 wherein L is selected from the structures:










where the wavy line indicates the attachment to R^5.

~~41~~26. The immunoconjugate of any one of claims 1 to ~~10~~7 having Formula Ia:



Ia.


~~42~~27. The immunoconjugate of claim ~~41~~26 wherein X^4 is a bond and R^4 is H.

~~43~~28. The immunoconjugate of claim ~~41~~26 wherein Cyc is selected from the group consisting of pyridyldiyl, pyrimidyldiyl, pyrazolyldiyl, piperazinyldiyl, piperidinyldiyl, and pyrazinyldiyl.


~~44~~29. The immunoconjugate of claim ~~41~~26 wherein X^2 and X^3 are each a bond, and R^2 and R^3 are independently selected from C_1-C_8 alkyl, –O–(C_1-C_{12} alkyl), –(C_1-C_{12} alkyldiyl)–OR^5, –(C_1-C_8 alkyldiyl)–$N(R^5)CO_2R^5$, –(C_1-C_{12} alkyl)–$OC(O)N(R^5)_2$, –O–(C_1-C_{12} alkyl)–$N(R^5)CO_2R^5$, and –O–(C_1-C_{12} alkyl)–$OC(O)N(R^5)_2$.

~~30~~45. The immunoconjugate of claim ~~41~~26 wherein X^2 is O.


~~46~~31. The immunoconjugate of claim ~~41~~26 selected from Formulae Ib-Ii:




Ib;




Ic;




Id;




Ie;




If;



Ig;




Ih; and




Ii .


~~47~~32. The immunoconjugate of claim ~~41~~26 selected from Formulae Ij-In:




Ij;




Ik;



Il;



Im; and




In .


~~48~~33. The immunoconjugate of claim ~~41~~26 wherein X^2 and X^3 are each a bond, and R^2 and R^3 are independently selected from C_1-C_8 alkyl, –O–(C_1-C_{12} alkyl), –(C_1-C_{12} alkyldiyl)–OR^5, –(C_1-C_8 alkyldiyl)–$N(R^5)CO_2R^5$, and –O–(C_1-C_{12} alkyl)–$N(R^5)CO_2R^5$.

~~49~~34. The immunoconjugate of claim ~~41~~26 wherein X^2 and X^3 are each a bond, R^2 is C_1-C_8 alkyl, and R^3 is selected from –O–(C_1-C_{12} alkyl) and –O–(C_1-C_{12} alkyl)–$N(R^5)CO_2R^5$.


~~50~~35. A 8-Cyc-2-aminobenzazepine-linker compound selected from ~~Tables 2a and 2b~~the group consisting of:




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;




;



;



; and



.

51[36]. An immunoconjugate prepared by conjugation of an anti PD-L1 antibody with a 8-Cyc-2-aminobenzazepine-linker compound selected from ~~Tables 2a and 2b~~claim 35.

52[37]. A pharmaceutical composition comprising a therapeutically effective amount of an immunoconjugate according to any one of claims 1 to ~~10~~7, and one or more pharmaceutically acceptable diluent, vehicle, carrier or excipient.

~~53. A method for treating cancer comprising administering a therapeutically effective amount of an immunoconjugate according to any one of claims 1 to 10, to a patient in need thereof, wherein the cancer is selected from bladder cancer, urinary tract cancer, urothelial carcinoma, lung cancer, non-small cell lung cancer, Merkel cell carcinoma, colon cancer, colorectal cancer, gastric cancer, and breast cancer.~~

~~54. The method of claim 53, wherein the cancer is susceptible to a pro-inflammatory response induced by TLR7 and/or TLR8 agonism.~~

~~55. The method of claim 53, wherein the cancer is a PD-L1-expressing cancer.~~

~~56. The method of claim 53, wherein the breast cancer is triple-negative breast cancer.~~

~~57. The method of claim 53, wherein the Merkel cell carcinoma cancer is metastatic Merkel cell carcinoma.~~

~~58. The method of claim 53, wherein the cancer is gastroesophageal junction adenocarcinoma.~~

~~59. The method of claim 53, wherein the immunoconjugate is administered to the patient intravenously, intratumorally, or subcutaneously.~~

~~60. The method of claim 53, wherein the immunoconjugate is administered to the patient at a dose of about 0.01 to 20 mg per kg of body weight.~~

~~61~~38. Use of an immunoconjugate according to any one of claims 1 to ~~49~~34 in the manufacture of a medicament for treating cancer, wherein the cancer is selected from cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, esophageal cancer, bladder cancer, urinary tract cancer, urothelial carcinoma, lung cancer, non-small cell lung cancer, Merkel cell carcinoma, colon cancer, colorectal cancer, gastric cancer, and breast cancer.

~~62~~39. A method of preparing an immunoconjugate of Formula I of claim 1 wherein the 8-Cyc-2-amino-thienoazepine-linker compound of ~~Tables 2a and 2b~~claim 35 is conjugated with the anti PD-L1 antibody.